Development of Special Biological Products.
Abstract
This report covers the following biological research and developments: (a) Rift Valley Fever (RVF) Vaccine Development - RVF vaccine was prepared and tested. Experiments were done and lots tested for residual live virus. Shipments of vaccine were made to Israel and USAMRIID. Submission for Lots 4 through 10 was prepared. A vaccine prepared in BHK-21 cells for animal use was delivered. A second lot of diagnostic antiserum was prepared and shipped. Disrupted RVF was sent to Dr. Milstien. Vaccine prepared by Agouza Institute was tested; (b) Rift Valley Fever (RVF) HA Antigen - Five liters of antigen were prepared; (c) Rift Valley Fever (RVF) H1849 Virus Strain - The H1849 strain of RVF virus was tested; (d) Rift Valley Fever (RVF) SA-51 Virus Strain- Growth curves and potency tests were done; (e) VEE (C-84) Vaccine Development - A pilot-run was conducted; (f) Venezuelan Equine Encephalomyelitis (VEE) Vaccine Immunizations - Plaque reduction neutralization tests were performed on sera from seven new employees; (g) Tissue Culture - Production lots of FRhL-2 and MRC-5 were stabilized and frozen. Two of the lots of FRhL-2 were certified; (h) Pasteurella Tularensis, Live - Seventeen vials of the SCHU-S5 strain were transferred to USAMRIID; and (i) Eastern Equine Encephalitis (EEE) Vaccine Development - Two hundred vials were shipped.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1980
- Accession Number
- ADA085351
Entities
People
- Chung K. Lee
- Donald E. Craig
- Joseph L. Demeio
- William J. Thomas